Based on K-M survival analysis, high TNFRSF12A expression group exhibited a lower disease-free survival (DFS) probability than low TNFRSF12A expression group (Figure 2B), indicating that STAD patients with a high TNFRSF12A expression may have a worse prognosis. The gene discussed is TNFRSF12A; the disease is gastric adenocarcinoma.